Brief: Silo Pharma Announces Positive Results From IND-Enabling Study Of SP-26
15/03/2023 12:57
March 15 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA ANNOUNCES POSITIVE RESULTS FROM IND-ENABLING
STUDY
OF SP-26 FOR FIBROMYALGIA
* SILO PHARMA INC - INTEND TO PURSUE FDA'S STREAMLINED
REGULATORY
PATHWAY FOR DRUG APPROVAL
* SILO PHARMA INC - ADVANCING OUR WORK WITH REGULATORY
PARTNERS TO
PREPARE PRE-INVESTIGATIONAL NEW DRUG PACKAGE FOR SP-26
Source text for Eikon: ID:nGNX1qxfdX
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement